Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Confidence intervals for the COVID-19 neutralizing antibody retention rate in the Korean population

  • Apio, Catherine (Interdisplinary Program in Bioinformatics, Department of Statistics, Seoul National University) ;
  • Kamruzzaman, Md. (Department of Statistics, Seoul National University) ;
  • Park, Taesung (Interdisplinary Program in Bioinformatics, Department of Statistics, Seoul National University)
  • Received : 2020.09.19
  • Accepted : 2020.09.22
  • Published : 2020.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. No specific therapeutic agents or vaccines for COVID-19 are available, though several antiviral drugs, are under investigation as treatment agents for COVID-19. The use of convalescent plasma transfusion that contain neutralizing antibodies for COVID-19 has become the major focus. This requires mass screening of populations for these antibodies. While several countries started reporting population based antibody rate, its simple point estimate may be misinterpreted without proper estimation of standard error and confidence intervals. In this paper, we review the importance of antibody studies and present the 95% confidence intervals COVID-19 antibody rate for the Korean population using two recently performed antibody tests in Korea. Due to the sparsity of data, the estimation of confidence interval is a big challenge. Thus, we consider several confidence intervals using Asymptotic, Exact and Bayesian estimation methods. In this article, we found that the Wald method gives the narrowest interval among all Asymptotic methods whereas mid p-value gives the narrowest among all Exact methods and Jeffrey's method gives the narrowest from Bayesian method. The most conservative 95% confidence interval estimation shows that as of 00:00 on September 15, 2020, at least 32,602 people were infected but not confirmed in Korea.

Keywords

Acknowledgement

The authors thank Dr. Asaph Young Chun, Ph.D., Director-General, Statistics Research Institute Statistics, Korea for his extremely helpful comments.

References

  1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199-1207. https://doi.org/10.1056/NEJMoa2001316
  2. WHO director-general's opening remarks. Geneva: World Health Organization, 2020. Accessed 2020 Sep 19. Available from: https://www.who.int/dg/speeches/detail/who-director-generals-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
  3. Daily number of new reported cases of COVID-19 by country worldwide. Solna: European Centre for Disease Prevention and Control, 2020. Accessed 2020 Sep 19. Available from: https://opendata.ecdc.europe.eu/covid19/casedistribution/csv.
  4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-1242. https://doi.org/10.1001/jama.2020.2648
  5. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis 2020 Apr 19 [Epub]. https://doi.org/10.1093/cid/ciaa461.
  6. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020;20:269-270. https://doi.org/10.1038/s41577-020-0308-3
  7. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020;14:69-71. https://doi.org/10.5582/bst.2020.01020
  8. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory diagnosis of COVID-19: current issues and challenges. J Clin Microbiol 2020;58:e00512-20.
  9. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20:398-400. https://doi.org/10.1016/S1473-3099(20)30141-9
  10. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582-1589. https://doi.org/10.1001/jama.2020.4783
  11. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007;357:1450-1451. https://doi.org/10.1056/NEJMc070359
  12. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011;52:447-456. https://doi.org/10.1093/cid/ciq106
  13. Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003;9:309.
  14. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24:44-46. https://doi.org/10.1007/s10096-004-1271-9
  15. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26:845-848. https://doi.org/10.1038/s41591-020-0897-1
  16. Antibody test to check if you've had coronavirus. London: NHS, 2020. Accessed 2020 Sep 19. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/testing-and-tracing/antibody-test-to-check-if-youve-had-coronavirus/.
  17. Antibody (serology) testing for COVID-19: information for patients and consumers. Silver Spring: Food and Drug Administration, 2020. Accessed 2020 Sep 19. Available from: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/antibody-serology-testing-covid-19-information-patients-and-consumers.
  18. Coronavirus (COVID-19): antibody testing. London: Department of Health and Social Care, 2020. Accessed 2020 Sep 19. Available from: https://www.gov.uk/government/publications/ coronavirus-covid-19-antibody-tests/coronavirus-covid-19-antibody-tests.
  19. Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun 2020;11:4059. https://doi.org/10.1038/s41467-020-17892-0
  20. S. Korea begins coronavirus antibody tests. Seoul: Yonhap News Agency, 2020. Accessed 2020 Sep 19. Available from: https://en.yna.co.kr/view/AEN20200630007300320.
  21. Spanish antibody study shows 5% of population exposed to coronavirus. New York: Reuters, 2020. Accessed 2020 Sep 19. Available from: https://www.reuters.com/article/us-health-coronavirus-spain-study-idUSKBN2471AL.
  22. 1 vs. 3,055: Koreans' rate of Covid-19 antibodies. Seoul: Korea Biomedical Review, 2020. Accessed 2020 Sep 19. Available from: https://www.koreabiomed.com/news/articleView.html?idxno=8732.
  23. Agresti A. Categorical Data Analysis. 3rd ed. Hoboken: John Wiley& Sons, 2013. pp. 12-16.
  24. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-413. https://doi.org/10.1093/biomet/26.4.404
  25. Agresti A. An Introduction to Categorical Data Analysis. Hoboken: John Wiley & Sons, 2018. pp. 11-16.
  26. Dobson AJ, Barnett AG. An Introduction to Generalized Linear Models. Boca Raton: CRC Press, 2018. pp. 229-238.